免疫PCR法检测乳腺癌患者血清p185抗体的临床价值

目的 以免疫PCR法来检测乳腺癌患者血清中的p185抗体,并研究血清p185抗体在乳腺癌血清学诊断、预后判断以及疗效判断中的临床价值.方法 选取2008年至2010年期间就诊的经病理确认手术切除乳腺癌患者60例,所有乳腺癌患者均在术后7～10天左右接受常规方案化疗.收集患者术前、术后并三次化疗结束后血清,同时收集健康体检者血清60份.利用本实验室建立的免疫PCR法分别检测样本的血清p185抗体,并分析血清p185抗体与患者肿块大小、临床分期、淋巴结转移情况、绝经状态、雌激素受体（ER）、孕激素受体（PR）的关系.用卡方检验同时分析检测p185抗体对乳腺癌不同化疗方案的疗效评判及与复发转移的关系.结果 乳腺癌患者血清p185抗体阳性率为30％（18/60）,明显高于非癌者（P＜0.01）;乳腺癌患者血清p185抗体与肿瘤大小（x2=11.428,P＜0.05）、临床分期（x2=9.965 8,P＜0.05）关系密切,但与绝经状态、雌激素受体状态（ER）、孕激素受体状态（PR）、淋巴结转移情况等因素均无关系（P＞0.05）.乳腺癌患者接受两种不同的化疗方案（CAF/CEF）治疗结束后血清p185抗体阳性表达二者之间无明显差异（x2 =0.051,P＞0.05）.乳腺癌患者血清p185抗体阳性患者复发转移率高于p185抗体阴性患者,二者之间有明显差异（x2=2.147,P＜0.05）.结论 免疫PCR法检测血清P185抗体可望为乳腺癌的早期诊断、复发转移的监测及预后判断提供了一种简单易行的方法.

Clinical value of immune-PCR for detecting p185 antibody in serum of patients with breast cancer

Objective Detect p185 antibody levels in serum with immune PCR method for breast cancer patients. Explore the clinical value of serum p185 antibody for diagnosis, prognosis and curative effect assessment of breast cancer. Methods 60 breast cancer patients who were diagnosed pathologically and received resection operation during 2008 and 2010 were included in this study, all the patients received conventional chemotherapy 7 - 10 days postoperative. Serum samples were collected from patients preoperative and post chemotherapy, andcollected another 60 serum samples from healthy volunteers. Detect the levels of p185 antibody in serum by using immune PCR method established in our laboratory, and explore the correlations between p185 antibody levels in serum and tumor size, clinical stage, lymph node metastasis, menopausal status, estrogen receptor （ER）, progesterone receptor （PR）, analysis the relationship between p185 antibody levels and curative effect assessment of chemotherapy, recurrence and metastasis. Results The positive rate of serum p185 antibody in breast cancer patients was 30% （ 18/60）, significantly higher than that in control group （P 〈0. 01 ） ; P185 antibody levels in serum was correlated to tumor size （ X2 = 11. 421, P 〈 O. 05 ） and clinical stage （ X2 = 9. 145, P 〈 O. 05 ）, but present no significant correlations with menopausal status, estrogen receptor（ ER）, PR receptor （PR） and lymph node metastasis （P 〉 0. 05 ）. The positive rate of p185 antibody in serum of patients received different chemotherapy regimens （CAF/CEF） present no significant difference （ X2 = O. 051, P 〉 0. 05 ）. The metastasis rate of patients positive in p185 antibody was higher than patients negative in p185 antibody （ X2 = 2. 147, P 〈 0. 05）. Conclusions The immune-PCR assay might be a method which can be used in breast cancer diagnose, recurrence and metastasis supervising, prognosis assessment.